A 52-year-old man from Delhi presents with a 2-month history of progressive weakness, bleeding gums, and petechiae. On examination, he has hepatosplenomegaly and generalized lymphadenopathy. Complete blood count shows Hb 6.8 g/dL, WBC 1200/μL, and platelets 35,000/μL. Bone marrow examination reveals hypocellular marrow with <25% cellularity and no dysplasia. Flow cytometry of blood is normal. Cytogenetics show 46,XY with no clonal abnormality. Which investigation is most critical to exclude before diagnosing aplastic anemia?

Explanation

## Diagnostic Workup of Hypocellular Pancytopenia **Key Point:** Before diagnosing aplastic anemia, inherited bone marrow failure syndromes (especially Fanconi anemia) must be excluded using chromosomal breakage tests (DEB or MMC), as they have different treatment implications and prognosis. ### Why Chromosomal Breakage Test Is Critical This patient presents with: - Hypocellular bone marrow (<25% cellularity) - Pancytopenia (Hb 6.8, WBC 1200, platelets 35,000) - Hepatosplenomegaly and lymphadenopathy - Normal cytogenetics (46,XY, no clonal abnormality) - Normal flow cytometry (excludes MDS and acute leukemia) **The presence of hepatosplenomegaly and lymphadenopathy raises concern for an inherited bone marrow failure syndrome**, particularly **Fanconi anemia (FA)**, which can present with: - Hypocellular marrow - Pancytopenia - Organomegaly - Increased risk of malignancy - Increased chromosomal fragility **DEB (diepoxybutane) or MMC (mitomycin C) test** is the gold-standard diagnostic test: - Fanconi anemia cells show **excessive chromosomal breaks and radial figures** when exposed to DEB/MMC - Normal individuals show minimal breakage - This test is **essential before initiating immunosuppressive therapy or hematopoietic stem cell transplantation (HSCT)**, as FA patients have increased sensitivity to alkylating agents and poor HSCT outcomes with standard conditioning ### Pancytopenia Workup Algorithm ```mermaid flowchart TD A[Pancytopenia + Hepatosplenomegaly]:::outcome --> B{Bone marrow cellularity?}:::decision B -->|Hypocellular| C[Exclude secondary causes]:::action B -->|Normocellular/Hypercellular| D[Consider MDS, hemolysis, sequestration]:::action C --> E[Viral serology, toxins, drugs]:::action E --> F{Flow cytometry and cytogenetics normal?}:::decision F -->|Yes| G[Suspected aplastic anemia]:::outcome G --> H[DEB/MMC test for FA]:::action H -->|Positive| I[Fanconi anemia diagnosed]:::urgent H -->|Negative| J[Proceed with aplastic anemia workup]:::action I --> K[Avoid alkylating agents, consider fludarabine-based HSCT]:::action J --> L[Immunosuppressive therapy or HSCT with standard conditioning]:::action ``` **Clinical Pearl:** Fanconi anemia can present in adulthood with aplastic anemia-like features. The presence of organomegaly should always prompt DEB/MMC testing, as missing this diagnosis can lead to catastrophic outcomes with standard aplastic anemia treatment (cyclophosphamide, ATG). **High-Yield:** The DEB/MMC test is **mandatory before any treatment** in suspected aplastic anemia with risk factors for FA (organomegaly, short stature, skeletal abnormalities, family history, or early-onset pancytopenia). **Mnemonic:** **FA-CHOP** = Fanconi Anemia features: **F**requent infections, **A**plas­tic anemia, **C**ancer predisposition, **H**ematologic abnormalities, **O**rganomegaly, **P**ancytopenia. **Warning:** ~~Aplastic anemia is always acquired~~ — Fanconi anemia can present as acquired-appearing aplastic anemia in adulthood. Always test for FA before treating with immunosuppression or standard-dose HSCT conditioning.